Medicago Group
Company Information
Medicago was a Quebec biopharmaceutical company known for plant-based virus-like particle vaccine technology. The company developed COVIFENZ, a plant-derived COVID-19 vaccine, and built its platform around using plants as bioreactors to produce vaccine and protein candidates. Although Medicago’s operations were terminated in 2023, it remains notable in Canadian biotech for advancing plant-based vaccine manufacturing.
Industry Focus and Technologies
Biologics, plant-based vaccines, virus-like particle technology, recombinant protein production, vaccine development, molecular farming, and biopharmaceutical manufacturing.
Location
Quebec City, Quebec, Canada
Company Size and Stage
Products, Platforms or Focus Areas
Plant-derived virus-like particle vaccine platform, COVIFENZ COVID-19 vaccine technology, and plant-based recombinant protein production systems for vaccine and biologic development.